Neurocrine Biosciences (Nasdaq: NBIX) has announced positive results from its Phase IV KINECT-PRO study, showing that ...

Biosciences announced top-line data from a Phase 4 study, KINECT-PRO, demonstrating clinically meaningful and sustained ...

GOTHENBURG, SWEDEN / ACCESS Newswire / February 27, 2025 / IRLAB Therapeutics (STO:IRLAB-A)(FRA:6IRA) Gothenburg, Sweden, February 27, 2025 - IRLAB Therapeutics AB (Nasdaq Stockholm: IRLAB A), a compa ...

GOTHENBURG, SWEDEN / ACCESS Newswire / February 27, 2025 / IRLAB Therapeutics (STO:IRLAB-A)(FRA:6IRA) Gothenburg, Sweden, ...

GOTHENBURG, SWEDEN / ACCESS Newswire / February 20, 2025 / IRLAB Therapeutics (STO:IRLAB-A)(FRA:6IRA) Gothenburg, Sweden, 20 February, 2025 - IRLAB Therapeutics AB (Nasdaq Stockholm: IRLAB a company d ...

Assemblyman Jeff Gonzalez (R-Indio) announced Monday the introduction of AB 641, which would create a public awareness ...

According to reports, Verma cited uninspiring guidance for the company's leading drug, Ingrezza (a treatment for movement disorder tardive dyskinesia). Management proffered guidance for Ingrezza ...

Additionally, it has been used for depression, attention deficit hyperactivity disorder (ADHD), Alzheimer's disease, autism, and tardive dyskinesia. Currently, the effects of DMAE aren't ...

Wedbush analyst Laura Chico lowered the firm’s price target on Neurocrine (NBIX) to $147 from $157 and keeps an Outperform rating on the ...

Eight years after introducing the first treatment for tardive dyskinesia, we're on track to once again achieve double-digit year-over-year growth this year. While our guidance reflects a moderated ...

Neurocrine Biosciences stock is a buy due to robust sales growth, augmented by the FDA approval of CRENESSITY in December 2024. INGREZZA dominates current sales, but CRENESSITY, a new treatment ...

Tardive dyskinesia can affect many areas of your life, including your social life and self-confidence. Learning how to manage these effects can help improve your overall well-being and daily ...